Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Osteoporosis Drug Stops Growth of Breast Cancer Cells, Even in Resistant Tumors

By BiotechDaily International staff writers
Posted on 03 Jul 2013
A drug approved in Europe to treat osteoporosis has now been shown to suppress the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies.

Presented on June 15, 2013, at the annual Endocrine Society meeting in San Francisco (CA, USA), the findings demonstrate that the drug bazedoxifene triggers a formidable one-two punch that not only blocks estrogen from promoting breast cancer-cell growth, but also targets the estrogen receptor for destruction.

“We found bazedoxifene binds to the estrogen receptor and interferes with its activity, but the surprising thing we then found was that it also degrades the receptor—it gets rid of it,” said senior author Donald McDonnell, PhD, chair of Duke Cancer Institute’s (Durham, NC, USA) department of pharmacology and cancer biology.

In animal and cell culture studies, the drug suppressed growth both in estrogen-dependent breast cancer cells and in cells that had developed resistance to the antiestrogen tamoxifen and/or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen-dependent breast cancer. Currently, if breast cancer cells develop resistance to these therapies, patients are usually treated with toxic chemotherapy agents that have significant side effects.

Bazedoxifene is an agent that, similar to tamoxifen, belongs to a class of drugs known as specific estrogen receptor modulators (SERMs). These drugs act like estrogen in some tissues, while substantially blocking estrogen action in other tissues. However, unlike tamoxifen, bazedoxifene has some of the characteristics of a newer group of drugs called selective estrogen receptor degraders (SERDs), which can target the estrogen receptor for destruction.

“Because the drug is removing the estrogen receptor as a target by degradation, it is less likely the cancer cell can develop a resistance mechanism because you are removing the target,” said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell’s lab. Many researchers had presumed that once breast cancer cells developed resistance to tamoxifen; however, “We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed,” he said.

The investigators evaluated a range of breast cancer-cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib; another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also strongly inhibited cell growth.

Ironically, in bone tissue, bazedoxifene mirrors the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and effectiveness studies as a treatment for osteoporosis, it may be a feasible near-term alternative for patients with advanced breast cancer whose tumors have become resistant to other treatment approaches, Dr. Wardell reported. In clinical trials, the most frequently reported side effect was hot flashes in the bazedoxifene treatment groups.

The study was funded by a research grant from Pfizer Pharmaceuticals (New York, NY, USA), maker of bazedoxifene.

Related Links:

Duke Cancer Institute





comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A leukemia cell coated with antibody is marked for destruction by activated natural killer cells (Photo courtesy of the University of Southern California).

Leukemia Cells Are Killed in Culture by Immune Cells Grown from the Same Patient

Immune system natural killer (NK) cells were isolated from leukemia patients, expanded in culture, and then shown in an in vitro system to attack and destroy cancer cells from the original cell donors.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.